4//SEC Filing
Sharp Shalini 4
Accession 0000914475-24-000138
CIK 0000914475other
Filed
May 20, 8:00 PM ET
Accepted
May 21, 5:35 PM ET
Size
8.9 KB
Accession
0000914475-24-000138
Insider Transaction Report
Form 4
Sharp Shalini
Director
Transactions
- Exercise/Conversion
Common Stock
2024-05-17+2,100→ 2,100 total - Sale
Common Stock
2024-05-17$141.90/sh−1,106$156,943→ 994 total - Exercise/Conversion
Restricted Stock Unit
2024-05-17−2,100→ 0 total→ Common Stock (2,100 underlying)
Footnotes (4)
- [F1]The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on November 27, 2023. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- [F2]Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $140.81 to $142.33. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range
- [F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock.
- [F4]This RSU award was granted to the Reporting Person on May 17, 2023 and is fully vested.
Documents
Issuer
NEUROCRINE BIOSCIENCES INC
CIK 0000914475
Entity typeother
Related Parties
1- filerCIK 0001377202
Filing Metadata
- Form type
- 4
- Filed
- May 20, 8:00 PM ET
- Accepted
- May 21, 5:35 PM ET
- Size
- 8.9 KB